Nebenwirkungen · Phesgo
Phesgo 600 mg/600 mg solution for injection Phesgo 1 200 mg/600 mg solution for injection · Abschnitt 4.8 · PDF-Seite 17
HOS-147101 · Präparat HOS-099594
In neoadjuvant and adjuvant trials, pertuzumab was administered on the same day as the other study treatment. Infusion-related reactions occurred in 18.6 %-25 % of patients on the first day of pertuzumab administration (in combination with trastuzumab and chemotherapy). The type and severity of events were consistent with those observed in CLEOPATRA, with a majority of reactions being mild or moderate in severity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-28T11:50:00Z · SHA-256 a6c98bf6b55eca9607a319c3be5d77798ac324754cdfd92882fd80d342fc312e · Passage ae15f753e58d8d3d770341f21cfbcdc85257241dd91d8741c4e39e2085791240 · Zeichen 19276–19693 im Abschnitt